Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biologic response modifiers in pediatric cancer.

L L Worth1, S S Jeha, E S Kleinerman

  • 1Department of Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

Hematology/Oncology Clinics of North America
|October 26, 2001
PubMed
Summary

Biologic response modifiers are emerging cancer treatments that stimulate the immune system to eliminate residual disease. Incorporating these agents may improve survival rates for various malignancies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

Bone marrow transplantation·2016
Same author

Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines.

Oncogenesis·2013
Same author

Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia.

Bone marrow transplantation·2012
Same author

MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts.

Cell death & disease·2012
Same author

Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.

Bone marrow transplantation·2009
Same author

Interferon-alpha after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma.

Bone marrow transplantation·2006

Area of Science:

  • Oncology and Immunology

Background:

  • Biologic response modifiers (BRMs) are increasingly utilized alongside traditional cancer therapies like surgery, chemotherapy, and radiotherapy.
  • The field of BRM research is rapidly expanding, leading to their integration into diverse therapeutic strategies.

Purpose of the Study:

  • To explore the role of biologic response modifiers in cancer management.
  • To highlight the potential of BRMs in improving patient outcomes and survival rates.

Main Methods:

  • This study reviews the current landscape and future potential of biologic response modifiers in cancer treatment.
  • It focuses on the mechanism of immune system stimulation by BRMs.

Main Results:

  • Biologic response modifiers can stimulate the host immune system to target and eradicate minimal residual cancer cells.

Related Experiment Videos

  • This immune stimulation holds promise for enhancing disease-free and long-term survival in patients with various cancers.

    • Conclusions:

    • Biologic response modifiers represent a significant advancement in cancer therapy, offering a way to leverage the immune system.
    • The primary challenge lies in optimizing the use of BRMs to maximize their anti-tumor effects and therapeutic efficacy.